News

Pharmabiz2h
Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis
Sanofi announces tolebrutinib phase 3 study data published in NEJM shows benefit on disability progression in multiple sclerosis: Paris Thursday, April 10, 2025, 10:00 Hrs [IST] T ...
Multiple Sclerosis News Today8h
AI tool effectively measures MS disease activity from 1 MRI scan
A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...
Experimental drug shown to slow multiple sclerosis disability
An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...
Q&A: Study shows promise for treating progressive multiple sclerosis
New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...
HealthDay16h
Experimental Drug Shows Promise in Slowing Disability from Multiple Sclerosis
An experimental drug may slow the progression of a form of multiple sclerosis that increases disability relentlessly, a new ...
Young woman's feet felt numb, before long she was having a part of her brain removed
The 27-year-old woman had to have major brain surgery to correct a rare condition called Chiari Malformation, which means ...
PharmiWeb20h
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing ...